Literature DB >> 22564065

Evaluating the impact of community-based treatment options on methamphetamine use: findings from the Methamphetamine Treatment Evaluation Study (MATES).

Rebecca McKetin1, Jake M Najman, Amanda L Baker, Dan I Lubman, Sharon Dawe, Robert Ali, Nicole K Lee, Richard P Mattick, Abdullah Mamun.   

Abstract

AIMS: To evaluate the impact of community-based drug treatment on methamphetamine use using inverse probability of treatment-weighted (IPTW) estimators to derive treatment effects.
DESIGN: A longitudinal prospective cohort study with follow-ups at 3 months, 1 year and 3 years. Treatment effects were derived by comparing groups at follow-up. IPTW estimators were used to adjust for pre-treatment differences between groups.
SETTING: Sydney and Brisbane, Australia. PARTICIPANTS: Participants were methamphetamine users entering community-based detoxification (n = 112) or residential rehabilitation (n = 248) services and a quasi-control group of methamphetamine users (n = 101) recruited from the community. MEASUREMENTS: Frequency of methamphetamine use between interviews (no use, less than weekly, 1-2 days per week, 3+ days per week), continuous abstinence from methamphetamine use, past month methamphetamine use and methamphetamine dependence.
FINDINGS: Detoxification did not reduce methamphetamine use at any follow-up relative to the quasi-control group. Relative to quasi-control and detoxification groups combined, residential rehabilitation produced large reductions in the frequency of methamphetamine use at 3 months [odds ratio (OR) = 0.23, 95% confidence interval (CI) 0.15-0.36, P < 0.001), with a marked attenuation of this effect at 1 year (OR 0.62, 95% CI 0.40-0.97, P = 0.038) and 3 years (OR = 0.71, 95% CI 0.42-1.19, P = 0.189). The greatest impact was for abstinence: for every 100 residential rehabilitation clients there was a gain of 33 being continuously abstinent at 3 months, with this falling to 14 at 1 year and 6 at 3 years.
CONCLUSIONS: Community-based residential rehabilitation may produce a time-limited decrease in methamphetamine use, while detoxification alone does not appear to do so.
© 2012 The Authors. Addiction © 2012 Society for the Study of Addiction.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564065     DOI: 10.1111/j.1360-0443.2012.03933.x

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  26 in total

1.  Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors.

Authors:  Mary-Lynn Brecht; Diane Herbeck
Journal:  Drug Alcohol Depend       Date:  2014-03-12       Impact factor: 4.492

2.  Attenuated insular processing during risk predicts relapse in early abstinent methamphetamine-dependent individuals.

Authors:  Joshua L Gowin; Katia M Harlé; Jennifer L Stewart; Marc Wittmann; Susan F Tapert; Martin P Paulus
Journal:  Neuropsychopharmacology       Date:  2013-12-06       Impact factor: 7.853

3.  Methamphetamine Vaccines: Improvement through Hapten Design.

Authors:  Karen C Collins; Joel E Schlosburg; Paul T Bremer; Kim D Janda
Journal:  J Med Chem       Date:  2016-04-19       Impact factor: 7.446

4.  Addiction and treatment experiences among active methamphetamine users recruited from a township community in Cape Town, South Africa: A mixed-methods study.

Authors:  Christina S Meade; Sheri L Towe; Melissa H Watt; Ryan R Lion; Bronwyn Myers; Donald Skinner; Stephen Kimani; Desiree Pieterse
Journal:  Drug Alcohol Depend       Date:  2015-04-30       Impact factor: 4.492

5.  Abstinence to chronic methamphetamine switches connectivity between striatal, hippocampal and sensorimotor regions and increases cerebral blood volume response.

Authors:  Ji-Kyung Choi; Grewo Lim; Yin-Ching Iris Chen; Bruce G Jenkins
Journal:  Neuroimage       Date:  2018-03-05       Impact factor: 6.556

6.  Lipid tucaresol as an adjuvant for methamphetamine vaccine development.

Authors:  K C Collins; J E Schlosburg; J W Lockner; P T Bremer; B A Ellis; K D Janda
Journal:  Chem Commun (Camb)       Date:  2014-04-21       Impact factor: 6.222

7.  Patterns of treatment utilization and methamphetamine use during first 10 years after methamphetamine initiation.

Authors:  Mary-Lynn Brecht; Katherine Lovinger; Diane M Herbeck; Darren Urada
Journal:  J Subst Abuse Treat       Date:  2013-01-11

8.  Client incentives versus contracting and staff incentives: how care continuity interventions in substance abuse treatment can improve residential to outpatient transition.

Authors:  Shauna P Acquavita; Sandra Stershic; Rajni Sharma; Maxine Stitzer
Journal:  J Subst Abuse Treat       Date:  2013-01-30

9.  Influencing Antibody-Mediated Attenuation of Methamphetamine CNS Distribution through Vaccine Linker Design.

Authors:  Major Gooyit; Pedro O Miranda; Cody J Wenthur; Alex Ducime; Kim D Janda
Journal:  ACS Chem Neurosci       Date:  2016-12-16       Impact factor: 4.418

Review 10.  Responding to global stimulant use: challenges and opportunities.

Authors:  Michael Farrell; Natasha K Martin; Emily Stockings; Annick Bórquez; Javier A Cepeda; Louisa Degenhardt; Robert Ali; Lucy Thi Tran; Jürgen Rehm; Marta Torrens; Steve Shoptaw; Rebecca McKetin
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.